title: Pharmacogenetics and cost-effectiveness analysis: a two-way street.
abstract: Genetic and proteomic information can be used to identify those patient groups who are most susceptible to a disease and those who are most likely to respond to particular pharmacological treatments. In this review we discuss the impact of cost-effectiveness analysis (CEA) regarding the way pharmacogenetics are adopted by healthcare systems and also, the potential impact of pharmacogenetics on the way CEA is conducted. We conclude that, although CEA can help incentivise the development of appropriate pharmacogenetic tests, when used inappropriately by payers or when ignored by developers, it can act as an obstacle to the adoption of health and efficiency improving technologies.
authors: National Institute for Health and Clinical Excellence, UK. Kalipso.Chalkidou@nice.org.uk
authors: Kalipso
authors: K
authors: Chalkidou
authors: Michael
authors: M
authors: Rawlins
mesh_terms: D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics*; D064420:Drug-Related Side Effects and Adverse Reactions; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000191:economics*; D006801:Humans; D019458:Insurance Coverage; D025202:Molecular Diagnostic Techniques / Q000191:economics*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D010597:Pharmacogenetics / Q000191:economics*; D040901:Proteomics / Q000191:economics
chemical_list: D004364:Pharmaceutical Preparations